ZIOPHARM Receives Notices of Allowance for Two U.S. Patent Applications Covering anticancer drug Darinaparsin

ZIOPHARM announced that it has received Notices of Allowance from the USPTO for patent applications which covers claims for various organic arsenic compounds, including purified crystalline Darinaparsin, glycolic arsenicals, and the oral pharmaceutical composition of an organic arsenic compound, and their use in the treatment of cancer. A notice of allowance signifies that the applicant is entitled to a patent under the U.S law.